Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum

Harvard Bioscience, Inc. (Nasdaq: HBIO) has announced its participation in the upcoming Virtual Healthcare Forum hosted by KeyBanc Capital Markets. Scheduled for Tuesday, March 17th, 2026, the event will feature a fireside chat with John Duke, President and CEO, alongside Mark Frost, Interim CFO. This discussion is set to begin at 2:15 PM ET and will be accessible via an audio-only webcast on the company’s investor relations website.

Harvard Bioscience is recognized as a prominent developer and supplier of cutting-edge technologies and products aimed at facilitating advancements in life sciences. Their offerings play a vital role in various crucial applications, including research, drug discovery, bioproduction, and preclinical testing. This broad range of services caters to a diverse client base, which includes leading academic institutions, government research entities, and top-tier pharmaceutical and biotechnology companies, as well as contract research organizations.

With a global presence that spans the United States, Europe, and China, Harvard Bioscience employs a hybrid distribution model to reach its extensive customer network. This approach allows the company to effectively deliver its innovative solutions to the life sciences sector worldwide.

As the industry increasingly pivots toward integrating advanced technologies into research and development processes, events like the KeyBanc Virtual Healthcare Forum provide crucial platforms for companies such as Harvard Bioscience to showcase their expertise and developments. Stakeholders interested in the event can find further details and access the webcast through the company’s events and presentations page on its investor relations portal.

For additional inquiries, Mark Frost, the Interim CFO, can be reached directly at 508-893-3120 or via email at investors@harvardbioscience.com. For more information about Harvard Bioscience and its offerings, visit their official website at www.harvardbioscience.com.

As Harvard Bioscience, Inc. (Nasdaq: HBIO) prepares to participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on March 17, 2026, investors should consider both the company's positioning in the life sciences sector and the potential implications of this engagement.

Harvard Bioscience is a notable manufacturer and developer of technologies that support a wide array of life science applications, including critical areas such as pharmaceutical and therapy discovery and bio-production. This diverse customer base, ranging from prestigious academic institutions to leading pharmaceutical firms, underscores the company's strong market position and relevance in areas that are crucial for ongoing biotechnological progress.

The upcoming fireside chat with CEO John Duke and Interim CFO Mark Frost presents a unique opportunity for investors to gain insights into the company's strategic direction and financial health. Given the heightened interest in biotechnology and healthcare innovation, participating in this forum could enhance investor confidence and lead to potential stock uptake, especially if the leadership shares optimistic projections or highlights new developments that could drive growth.

Investors should closely monitor the discussions during the forum for any signals regarding future business strategies, such as product launches or partnerships that can drive revenue. Additionally, this transparency can indicate the company's ability to navigate the complexities within the life sciences sector, particularly as it manages operations across multiple geographies, including the U.S., Europe, and China.

From a stock perspective, if Harvard Bioscience provides strong upward guidance or demonstrates innovative advancements, it could lead to an increase in price momentum. However, cautious investors should also consider market volatility and potential risks associated with biotechnology investments. Diversifying within the sector, while keeping an eye on Harvard Bioscience's developments, may be a prudent approach moving forward.